Trial Profile
A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ERIBRAIN
- 05 May 2020 Planned End Date changed from 28 Mar 2024 to 14 Apr 2020.
- 05 May 2020 Planned primary completion date changed from 16 Mar 2024 to 14 Apr 2020.
- 05 May 2020 Status changed from recruiting to withdrawn prior to enrolment.